As of March 31, 2024, cash, cash equivalents and short-term investments were $420.7 million, as compared to $583.4 million as of fiscal year March 31, 2023. The decrease was primarily related to cash utilized in operating activities in advancing the Company’s clinical development plans. Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of March 31, 2024 will enable the Company to fund operations into the second half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Is REPL a Buy, Before Earnings?
- Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy
- Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
- Replimune Group announces inducement grants under Nasdaq listing rule
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Questions or Comments about the article? Write to editor@tipranks.com